Biosimilars on the move in Asia

While the United States waits on the ruling of the healthcare act tomorrow, including the fate of Biosimilars in the US, from the Supreme Court tomorrow, many countries in Asia Pacific have are embracing the opportunity of biosimilars in their market.  Many of the countries in Asia Pacific have embraced this more cost effective form of treatment for their growing middle class, who often pays for health insurance out of their pockets.  Countries like China, India and Korea lead the way  in manufacturing and others including Japan, Australia, Singapore and Malaysia have regulations according to Pharma Phorum.  While many of these biosimilars companies have no experience in regulated markets, they are developing and distributing biosimilars to semi-regulated.  This gives them immense amounts of knowledge of the drugs, as the Asian biosimilars market accounts for 25% of the worldwide market.

This September in Boston, the Business of Biosimilars and Generic Drugs will hear from Andrew Shaw, Senior Director, PKDM, Mylan on the topic of globalizing generics and biosimilars.   It could be argued that America is an emerging market in biosimilars, and Shaw will be discussing that.  For more information on Shaw's presentation and the rest of the program, download the agenda here.  If you'd like to join us this September in Boston, register with code XP1786BLOG and save 25% off the standard rate.

What are the benefits of the companies operating in the semi-regulated markets to their business when they decide to expand in to a regulated market, such as the United States or Europe?

Share this article with your social network, just click below to share now!

Share |